Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-10-02Clinical Trial Update: Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. [Phase 2]
Phase II trial evaluating olaparib in combination with abiraterone for metastatic castration-resistant prostate cancer has completed with re…
-
CLINICAL_TRIALS trial_result · 2018-09-25Clinical Trial Update: A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer [Phase 2]
Phase 2 study evaluating sipuleucel-T with enzalutamide in metastatic castration-resistant prostate cancer has completed with results posted…
-
FDA label_change · 2018-08-31FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA supplemental application for XOFIGO (radium-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc. to support changes to the…
-
CLINICAL_TRIALS withdrawal · 2018-07-30Clinical Trial Update: Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents [Phase 3]
Phase 3 trial evaluating Orteronel as maintenance therapy in metastatic castration-resistant prostate cancer previously treated with novel h…
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL) [Phase 2]
A Phase 2 multicenter trial comparing Taxotere (docetaxel) plus Curcumin versus Taxotere plus placebo in first-line treatment of metastatic …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-07-13Clinical Trial Update: Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer [Phase 1, Phase 2]
Phase Ib/IIa trial evaluating cabazitaxel plus bavituximab in castration-resistant prostate cancer was terminated, with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2018-07-12Clinical Trial Update: Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel [NA]
This terminated trial evaluated dexamethasone prior to enzalutamide re-treatment in metastatic castration-resistant prostate cancer patients…
-
CLINICAL_TRIALS trial_result · 2018-07-12Clinical Trial Update: Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone [Phase 2]
Phase 2 trial comparing standard dose, high dose, and extended standard dose of Radium-223 dichloride in metastatic castration-resistant pro…
-
CLINICAL_TRIALS trial_result · 2018-06-26Clinical Trial Update: Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial update of Selinexor in patients with abiraterone and/or enzalutamide refractory metastatic castration-resistant prostate cance…
-
CLINICAL_TRIALS trial_result · 2018-06-08Clinical Trial Update: Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer [EARLY_Phase 1]
An early-phase pharmacodynamic study of radium-223 in men with bone-metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer [Phase 2]
A completed Phase 2 clinical trial evaluated the combination of metformin with docetaxel in patients with metastatic hormone-refractory pros…
-
CLINICAL_TRIALS trial_result · 2018-05-23Clinical Trial Update: Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer [Phase 3]
Phase 3 trial comparing cabozantinib (XL184) to mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant…
-
FDA approval · 2018-05-22FDA Approved: YONSA — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approval of Sun Pharmaceutical Industries' YONSA (abiraterone acetate) under an Original Application for the treatment of prostate cance…
-
CLINICAL_TRIALS trial_result · 2018-05-07Clinical Trial Update: Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer [Phase 2]
Phase 2 clinical trial update for VT-464 in patients with castration-resistant prostate cancer previously treated with enzalutamide, androge…
-
CLINICAL_TRIALS trial_result · 2018-04-27Clinical Trial Update: A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 [Phase 2]
Phase 2 trial update evaluating the safety of continuing enzalutamide (MDV3100) in men with castration-resistant prostate cancer who previou…
-
CLINICAL_TRIALS trial_result · 2018-04-19Clinical Trial Update: A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment [Phase 4]
Phase 4 study evaluating enzalutamide re-treatment in metastatic castration-resistant prostate cancer after prior docetaxel and/or cabazitax…
-
CLINICAL_TRIALS trial_result · 2018-04-18Clinical Trial Update: Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer [Phase 1]
Phase 1 trial evaluating the combination of niclosamide and enzalutamide in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A multicenter Phase I/II trial of Abiraterone Acetate plus BEZ235 in metastatic castration-resistant prostate cancer was terminated, with re…
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease [Phase 1, Phase 2]
CureVac completed a Phase 1/2 trial assessing the safety and efficacy of an RNActive-derived prostate cancer vaccine in patients with hormon…
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 study assessing the pharmacokinetic and pharmacodynamic response to Orteronel (TAK-700) in chemotherapy-naive patients with castra…
-
CLINICAL_TRIALS trial_result · 2018-03-14Clinical Trial Update: Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 [Phase 3]
Phase 3 study comparing cabozantinib to prednisone in men with metastatic castration-resistant prostate cancer previously treated with docet…
-
CLINICAL_TRIALS withdrawal · 2018-03-12Clinical Trial Update: Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating LE-DT for metastatic castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer [Phase 1]
This Phase 1 trial update reports safety, preliminary efficacy, and pharmacokinetics data for ASN001 in metastatic castration-resistant pros…
-
CLINICAL_TRIALS withdrawal · 2018-03-01Clinical Trial Update: Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial of EPI-506 for metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS research · 2018-02-28Clinical Trial Update: Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO) [NA]
Phase II randomized study evaluating SBRT with Abiraterone acetate versus Abiraterone acetate alone in oligometastatic metastatic castration…